Epix Pharmaceuticals, Inc. Announces a Change in the May 28, 2010 Auction Sale of Epix Imaging Agents to June 22, 2010

WELLESLEY HILLS, Massachusetts, May 21, 2010 - Joseph F. Finn, Jr., C.P.A. ("Finn"), Assignee for the Benefit of
Creditors of Epix Pharmaceuticals, Inc. ("Epix"), announced today that the
auction of the MRI imaging intellectual properties has been changed to June
22, 2010 at 9:00 A.M. Eastern. This was done to allow bidders to complete due
diligence on all three (3) gadolinium-based imaging programs. They consist of
1) MS-325 (gadofosveset trisodium), commercial MRA imaging agent, currently
marketed as Ablavar(R) in the US by Lantheus Medical Imaging and formerly
marketed as Vasovist(R), in Europe and other countries by Bayer Schering
Pharma. The MS-325 commercial rights for sale include Europe, Switzerland and
other regions outside the US, Canada, Puerto Rico and Australia, 2) EP-2104R,
a fibrin binding MRI imaging agent in Phase 2 clinical development for clot
detection; and 3) EP-3600, a collagen binding MRI imaging agent in
preclinical development for myocardial perfusion. Bidders may bid on any
combination of the three or all three.

The assets of Epix were transferred to him on July 20, 2009 and he is
liquidating them for the benefit of Epix creditors. He recently reached an
agreement with Bayer Schering Pharma that permits the sale of the MRI imaging
programs.

Persons interested in bidding must sign a Confidentiality Disclosure
Agreement ("CDA") obtained from Finn's Office -
IPSALESERVICES@FINNWARNKEGAYTON.COM or +1-781-237-8840. They will then
receive a bid package and access to an electronic data room.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the owner of the firm Finn, Warnke &
Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts. He
works primarily in the area of management consulting for distressed
enterprises, bankruptcy accounting and related matters, such as assignee for
the benefit of creditors and liquidating agent for a corporation. He has been
involved in a number of loan workouts and bankruptcy cases for thirty-five
(35) years. His most recent Assignments for the Benefit of Creditors in the
biotech field include Spherics, Inc., ActivBiotics, Inc. and Prospect
Therapeutics, Inc.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at
+1-781-237-8840 or IPSALESERVICES@FINNWARNKEGAYTON.COM

Joseph F. Finn, Jr., C.P.A., +1-781-237-8840, IPSALESERVICES at FINNWARNKEGAYTON.COM